newsfilter
← Latest News
Business Wire·

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

  • AbCellera (NASDAQ: ABCL) will release top-line Phase 2 data for ABCL635 before market open on Monday, August 10, 2026.
  • The company will host an investor conference call & live webcast at 4:30 a.m. PT (7:30 a.m. ET) on August 10, 2026.
  • ABCL635 is a first-in-class antibody targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause.
  • The drug entered the clinic in July 2025 as the first program from AbCellera's GPCR & ion channel platform.
  • The Phase 2 trial (NCT07118891) is a multicenter, randomized, double-blind, placebo-controlled study involving approximately 80 postmenopausal women.
  • A live audio webcast & replay will be accessible via a link on AbCellera's Investor Relations website.